Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.79 |
| ▸ | BCL2 | P10415 | 17/20 | 0.79 |
| ▸ | BAD | Q92934 | 4/20 | 0.79 |
| ▸ | BCL2L2 | Q92843 | 3/20 | 0.79 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.79 |
| ▸ | ASPH | Q12797 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21179253 | 1.00 | BCL2L1 (0.79) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL21179258 | 1.00 | BCL2L1 (0.79) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19014626 | 0.94 | BCL2L1 (0.82) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL20992957 | 0.93 | BCL2L1 (0.83) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL31283521 | 0.93 | BCL2L1 (0.75) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL21179139 | 0.93 | BCL2L1 (0.75) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL21179134 | 0.93 | BCL2L1 (0.75) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL24985389 | 0.93 | BCL2 (0.86) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL1628701 | 0.93 | BCL2 (0.86) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL1567618 | 0.93 | BCL2L1 (0.86) | BCL2L1BCL2BADBCL2L2BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12118414-B2 | BCL-2 proteins degraders for cancer treatment | BIOVENTURES, LLC (US) | 2024-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12118414-B2 | BCL-2 proteins degraders for cancer treatment | BCL2, BCL2L1, BCL2L2 | BCL2L1 2/4885BCL2 1/4885BAD 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.